Tiger Brokers

BUZZ-NovaBridge gains as eye disease drug shows promise in mid‑stage trial

Reuters
Mar 09
BUZZ-NovaBridge gains as eye disease drug shows promise in mid‑stage trial

** Shares of drug developer NovaBridge NBP.O rise 6.6% to $3.73 premarket

** Co says its experimental drug, VIS-101, improved vision in people with wet age-related macular degeneration, a disease that damages the retina and causes vision loss in older adults

** Adds patients gained more than 10 letters on a standard eye chart and had reduced retinal swelling in a mid-stage study

** Says nearly half of the 38 patients in the trial needed no additional treatment for six months after three doses

** VIS‑101 well tolerated with no serious safety issues - co

** NBP plans larger dose-finding study in second-half of 2026 and global late-stage trial in 2027

** Shares rose nearly four-fold in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10